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Abstract
Objective The putative mechanism for the favourable effect of endovascular treatment (EVT) on functional outcome after acute
ischaemic stroke is preventing follow-up infarct volume (FIV) progression. We aimed to assess to what extent difference in FIV
explains the effect of EVT on functional outcome in a randomised trial of EVT versus no EVT (MR CLEAN).
Methods FIV was assessed on non-contrast CT scan 5–7 days after stroke. Functional outcome was the score on the modified
Rankin Scale at 3 months. We tested the causal pathway from intervention, via FIV to functional outcome with a mediation
model, using linear and ordinal regression, adjusted for relevant baseline covariates, including stroke severity. Explained effect
was assessed by taking the ratio of the log odds ratios of treatment with and without adjustment for FIV.
Results Of the 500 patients included in MR CLEAN, 60 died and four patients underwent hemicraniectomy before
FIV was assessed, leaving 436 patients for analysis. Patients in the intervention group had better functional out-
comes (adjusted common odds ratio (acOR) 2.30 (95% CI 1.62–3.26) than controls and smaller FIV (median 53 vs.
81 ml) (difference 28 ml; 95% CI 13–41). Smaller FIV was associated with better outcome (acOR per 10 ml 0.60,
95% CI 0.52–0.68). After adjustment for FIV the effect of intervention on functional outcome decreased but
remained substantial (acOR 2.05, 95% CI 1.44–2.91). This implies that preventing FIV progression explains 14%
(95% CI 0–34) of the beneficial effect of EVT on outcome.
Conclusion The effect of EVT on FIVexplains only part of the treatment effect on functional outcome.
MR CLEAN Investigators are listed in the Appendix (Online
Supplementary Table 1)
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• Endovascular treatment in acute ischaemic stroke patients prevents progression of follow-up infarct volume on non-contrast CT
at 5–7 days.
• Follow-up infarct volume was related to functional outcome, but only explained a modest part of the effect of intervention on
functional outcome.
• A large proportion of treatment effect on functional outcome remains unexplained, suggesting FIValone cannot be used as an
early surrogate imaging marker of functional outcome.
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Abbreviations
CT Computed tomography
CTA Computed tomography angiography
DSA Digital subtraction angiography
EVT Endovascular treatment
FIV Follow-up infarct volume
MR CLEAN Multicenter Randomized
Clinical Trial of Endovascular
Treatment for Acute Ischemic Stroke
in The Netherlands
MRA Magnetic resonance angiography
MRI Magnetic resonance imaging
mRS Modified Rankin Scale
NCCT Non-contrast computed tomography
NIHSS National Institutes of Health Stroke Scale
Introduction
In 2015, endovascular treatment (EVT) was shown to be ef-
fective in improving functional outcome in patients with isch-
aemic stroke due to intracranial large vessel occlusion [1].
Secondary outcome analyses of the randomised clinical trials
also indicated significantly smaller infarct volumes at follow-
up imaging in patients who were allocated to the intervention
group [2, 3]. Studies have suggested that follow-up infarct
volume (FIV) could be a useful early outcome measure [4–6].
FIV as a surrogate outcome is a well-quantifiable measure
and therefore less sensitive to interobserver variability com-
pared to clinical assessment of functional outcome such as the
modified Rankin Scale score at 90 days [7, 8]. Also, FIV
measurements can be assessed relatively easily and semi-
automatically after treatment on non-contrast computed to-
mography (NCCT) or magnetic resonance imaging (MRI)
scans [9, 10]. Amoderate correlation between FIVand clinical
outcome has been demonstrated [11]. FIV has been suggested
as a primary endpoint in late phase II clinical trials, which are
intended to demonstrate an indication of therapeutic effect in
promising novel treatments. Assessment of functional out-
come as a clinical endpoint requires prolonged follow-up.
An early surrogate marker could therefore be more feasible
in clinical trials, and limit loss to follow-up [12, 13].
A recent post hoc study demonstrated that the beneficial
effect of EVT on functional outcome could be explained by
preventing progression of FIV, suggesting that the effect of
intervention on functional outcome is mediated by FIV [6].
Formal testing of such a mechanism requires a causal media-
tion model to estimate the extent to which the treatment effect
is explained by a mediator [14]. This is usually expressed as a
proportion of the original treatment effect. In the context of
testing a mediator as a surrogate marker, the Prentice criteria
have been proposed to formally test for a causal relation be-
tween surrogate and clinical endpoints [15]. This analytical
approach for estimating the causal effect of FIVon functional
outcome has not yet been fully reported for EVT in acute
ischaemic stroke and the extent to which the beneficial effect
of intervention on functional outcome can be explained by
difference in FIV is not yet known [16]. Understanding the
causal pathway of this relationmay provide further insight and
may help in developing surrogate markers of functional out-
come after EVT, and shed further light on outcome predictors
that can be used for future stroke trials. The aim of this study
was to assess whether and to what extent FIVon NCCTat 5–7
days’ follow-up is a mediator of the effect of intervention on
functional outcome in acute ischaemic stroke patients.
Material and methods
Patients
In this post-hoc analysis, we used data from the Multicenter
Randomised Clinical Trial of Endovascular Treatment for
Acute Ischemic Stroke in TheNetherlands (MRCLEAN), which
was performed at 16 Dutch stroke centres [2]. This randomised
trial investigated the effect of EVT plus usual care (intervention)
versus usual care only (control). In both treatment groups, ad-
ministration of intravenous alteplase was allowed before
randomisation. Patients had a minimal score of 2 on the
National Institutes of Health Stroke Scale (NIHSS) at baseline
and a radiologically confirmed proximal intracranial arterial oc-
clusion of the anterior circulation. Follow-up imaging by com-
puted tomography (CTA) or magnetic resonance angiography
(MRA) was done at 24 h to assess endovascular recanalisation.
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After 5–7 days, a (NCCT) scan was acquired to assess FIVand
haemorrhagic transformation. Institutional review board approv-
al and written informed consent from all patients were obtained
[2]. In the present study, patients were excluded if they died
before the follow-up NCCT scans at 5–7 days or in case no
NCCTwas acquired before hemicraniectomy.
Measures
FIVs at 5–7 days’ follow-up were semi-automatically seg-
mented with the use of validated in-house- developed soft-
ware based on intensity region growing algorithm [17].
Placement of seed points for initiating region growing in in-
farcted areas was done by an experienced radiologist to over-
come selection of older infarctions. Segmentations were
inspected and if necessary manually adjusted by two ob-
servers, who were blind to treatment allocation, as previously
described [9]. FIV was calculated by multiplying the number
of voxels with the voxel size. The semi-automated segmenta-
tions were highly correlated (Pearson’s correlation coefficient
of 0.98) to reference manual measurements [17]. Two exam-
ples of the semi-automatic segmentation process are shown in
Fig. 2. Post-treatment functional outcome was measured on
the modified Rankin Scale (mRS) at 90 days and was assessed
in a standardised telephone interview by a single investigator
and validated by blinded assessors. ThemRS is a 7-point scale
ranging from 0 (no symptoms) to 6 (death).
Statistical analysis
The confidence interval of the difference of measured median
FIVs between both treatment groups was tested by
bootstrapping with 1,000 replications. Statistical testing of a
mechanism or pathway requires a mediation model [14].
Rather than a direct causal relationship between the indepen-
dent variable (intervention or control group) and the depen-
dent variable (functional outcome), a mediation model pro-
poses that the independent variable influences the mediator
variable (FIVon NCCTat 5–7 days), which in turn influences
the dependent variable (Fig. 1).
Three requirements must be met to prove a true mediation
relationship [14]:
1) The independent variable must be a significant predictor
of the dependent variable (Fig. 1, pathway C).
2) The independent variable is a significant predictor of the
mediator (Fig. 1, pathway A).
3) The mediator is a significant predictor of the dependent
variable, while controlling for the independent variable.
In other words: when treatment allocation and FIV are
combined in one model to predict functional outcome
(i.e. pathway A-B), FIV should still be a significant pre-
dictor, while the effect of intervention should be strongly
reduced (compared to the unadjusted effect). This step is
needed to prove that the effect goes (partly) through path-
way A-B instead of C (Fig. 1).
According to the Prentice criteria, FIV must completely ac-
count for the net effect of intervention to be a perfect surrogate,
meaning that in step 3 the effect of intervention on functional
outcome should be reduced to a non-significant odds ratio [15].
In patients with missing FIVs, values of infarcted volumes
were imputed based on relevant baseline covariates, allocated
treatment and functional outcome [18]. Due to a skewed dis-
tribution of FIV measurements, the confidence interval of the
difference of measured median FIVs between both treatment
groups was constructed by bootstrapping with 1,000 replica-





achieve linearity for linear regression. Pathway A was tested
with linear regression. Pathways B, C and A-B were tested
with proportional odds regression without and with adjust-
ments for age, sex, previous diabetes mellitus, previous isch-
aemic stroke, atrial fibrillation, NIHSS at baseline, occluded
internal carotid artery terminus (ICA-T) occlusion, collateral
status at baseline CTA, treatment with intravenous alteplase
and time from stroke onset to randomisation. Effect estimates
were presented as common odds ratios and betas with corre-
sponding 95% confidence intervals (CIs). To assess the pro-
portion of the effect of intervention on functional outcome that
was mediated by FIV, the log odds ratio of the indirect effect
of intervention in pathway A-B was divided by the log odds
ratio of the direct effect of intervention in pathway C [19, 20].
The CIs for the proportion of the effect mediated were con-
structed with bootstrapping with 1,000 replications. In this
approach, the 95% CI can exceed 0% and 100% but we
Fig. 1 Causal diagram showing
the mediation model. Arrows are
the causal direction or possible
association
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manually truncated the lower bound to 0% and the upper
bound to 100%.
All analyses were performed in R statistical software (ver-
sion 3.4.2) with the packages foreign, rms, gvlma and boot.
Sensitivity analysis
To test the robustness of our findings against the assumptions that
were made, we performed two sensitivity analyses. First, in order
to account for patients who died within a week and therefore did
not have a NCCTat 5–7 days and for patients who had no NCCT
before hemicraniectomy, we imputed FIV in these patients with
single imputation. Second, we assessed the effect of replacing
missingFIVwith FIVassessed fromNCCTscans acquired at 24 h.
Results
Descriptives
In total, 500 patients were included in the MR CLEAN trial.
Sixty patients died before the NCCT scan at 5–7 days after
initial treatment could be performed and in four patients no
NCCT was performed before hemicraniectomy, leaving 436
patients for analysis (Fig. 3). In 99 (23%) of these 436 patients
no NCCT scan was made within 1 week because of logistic
reasons (n=91) such as transfer back to referring primary
stroke centre or hospital discharge or no FIV measurement
could be done because of poor scan quality (n=8). Baseline
characteristics of analysed patients in both treatment groups
are shown in Table 1, median measured FIV in all patients was
67 ml (IQR 30–124). Imaging outcomes regarding reperfu-
sion on digital subtraction angiography (DSA) and
recanalisation on follow-up CTA (24 h) of analysed patients
are presented in Tables 2 and 3.
Mediation analysis
In step 1 of the mediation analysis, we tested the relationship
between intervention and functional outcome. Treatment was
indeed a significant predictor of functional outcome. In the
present dataset, the adjusted common odds ratio (acOR) was
2.30 (95% CI 1.62–3.26). In step 2, we tested the relationship
between allocated treatment and FIV. The median FIV was 53
Fig. 2 Case examples of follow-
up infarct (FIV) segmentation on
non-contrast CT, acquired
between 5 and 7 days after onset.
(a and b) A 56-year-old male
with right-sided M1 occlusion.
FIV was 292 ml and this patient
was severely disabled at 90 days
(mRS 5). (c and d) A 45-year-
old female with right-sided M1
occlusion. FIV was 10 ml and the
patient showed no significant
disability at 90 days, despite some
symptoms (mRS 1)
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ml (IQR 24–116) in the intervention group and 81 ml (IQR
35–127) in the control group (difference 28 ml; 95% CI 13–
41). Intervention was significantly related to reduction in
transformed FIV with a beta of -0.37 (95% CI -0.65 –
-0.09). In step 3, we tested the relationship between FIV and
functional outcome, with adjustment for treatment allocation.
The mediator FIV was an independent variable and a signifi-
cant predictor of functional outcome with cOR of 0.60 (95%
CI 0.52–0.67) per 10 ml. The direct effect of intervention on
functional outcome remained statistically significant after ad-
justment for FIV with an acOR 2.05 (95% CI 1.44–2.91)
(Table 4). We found that preventing progression of FIV ex-
plains 14% (95% CI 0–34) of the beneficial effect of interven-
tion on functional outcome. All unadjusted estimates were
comparable to adjusted estimates.
Sensitivity analysis
In the first sensitivity analysis, including all patients, 35 pa-
tients in the intervention group and 29 patients in the control
group who died within 1 week or underwent hemicraniectomy
before NCCT were additionally included by single imputa-
tion. The results of the steps were consistent with the primary
analysis (Table 4). The proportion of explained mediated ef-
fect was 12% (95% CI 0–43). In the second sensitivity anal-
ysis, the missing 5–7 days NCCT FIV were replaced by 24-h
NCCT if performed instead of imputation (leaving 30 missing







Sex (men) (%) 117 (59.1) 134 (56.3) 41 (64.1)
Age (y, median [IQR]) 63.47 [53.3 - 73.4] 65.67 [55.1 - 76.4] 71.40 [61.8 – 79.9]
Pre-stroke mRS≤2 (%) 191 (96.5) 229 (96.2) 59 (92.2)
NIHSS at baseline (median [IQR]) 17.00 [14.0 - 20.8] 17.00 (14.0 - 21.8) 21.00 [17.0 – 23.0]
Treatment with intravenous alteplase (%) 177 (89.4) 216 (90.8) 52 (81.2)
Time from onset to randomisation (median [IQR]) 200.00 [150.0 - 250.0] 194.00 [148.8 - 266.8] 212.00 [174.0 – 258.3]
Smoking (%) 59 (29.8) 72 (30.3) 12 (18.8)
Diabetes (%) 23 (11.6) 29 (12.2) 16 (25.0)
Atrial fibrillation (%) 54 (27.3) 65 (27.1) 16 (25.0)
Previous stroke (%) 23 (11.6) 20 (8.4) 11 (17.2)
Location of intracranial occlusion (%) #
ICA 1 (0.5) 3 (1.3) -
ICA terminus 50 (25.3) 65 (27.3) 19 (29.7)
M1 129 (65.2) 146 (61.6) 44 (68.8)
M2 17 (8.6) 21 (8.9) 1 (1.6)
A2 1 (0.5) 2 (0.8) -
ASPECTS ≥ 8 (%) § 150 (75.0) 194 (82.6) 32 (50.8)
§ Alberta Stroke Program Early Computed Tomography Score (ASPECTS) ranges from 0 to 10, with higher scores indicating fewer early ischaemic
changes. Data were missing for three patients in the control group
# Location of intracranial occlusion could not be assessed in one patient in the control group due to non-performed vessel imaging
IQR interquartile range
Fig. 3 Flowchart of included patients in the primary analysis
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FIVs) and resulted in an explained mediated effect of 15%
(95% CI 0–38).
Discussion
In this study, we tested with mediation analysis whether the
beneficial effect of intervention for acute ischaemic stroke on
functional outcome could be explained by FIV. We found that
FIVon NCCT at 5–7 days was affected by treatment, and was
related to functional outcome, but only explained a modest
part of the effect of intervention on functional outcome at 90
days measured by the modified Rankin scale in patients with
acute ischaemic stroke. This implies that FIVon NCCT only
partially explains the effect of intervention on functional out-
come and should therefore not be used as an early surrogate
imaging marker for clinical endpoints in trials.
A previous study found a significant association between
volume of FIV on NCCT and three different functional out-
come measurements at 3 months. However, a moderate corre-
lation between infarct volume and all functional outcome
measures was found [11]. The study did not report the com-
monly used mRS score as a functional outcome measurement.
Another study, which also included ischaemic stroke patients
undergoing intervention, demonstrated that FIV was an im-
portant determinant of functional outcome at 3 months [4].
However, this study used imaging (NCCTor MRI) in a broad
time window between 24 h and 2 weeks after stroke. Our
conclusion also differs from a previous study on this topic,
which concluded that FIV explains the effect of intervention
on functional outcome [6]. However, in that study only the
first and second step of mediation analysis were performed,
and not the third step. This implies that no definite conclusion
on mediation could be drawn, which explains the discrepancy
with our findings. No other studies that reported an association
between FIV and functional outcome did not perform a full a
causal mediation analysis. In the REVASCAT study a media-
tion analysis was carried out, with similar results, but the pro-
portion of explained treatment effect was not estimated [16].
Our study is the first full mediation analysis to analyse the
pathway from intervention to FIV to functional outcome and
report the proportion of explained treatment effect mediated
by FIV.
Several assumptions must be made to perform an unbiased
causal mediation analyses [21]. First, there is no unmeasured
confounding between treatment and outcome; this assumption
Table 2 Explained proportions and effect sizes in the mediation analyses of the effect of intervention on functional outcome mediated by follow-up
infarct volume (FIV)











Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI)
A ( X→M ) Beta -0.34 (-0.64 – -0.05) Beta -0.37 (-0.65 – -0.09) -0.21 (-0.49 – 0.06) -0.38 (-0.64 – -0.11)
B ( M→ Y ) cOR 0.59 (0.52 – 0.66) acOR 0.58 (0.51 – 0.66) 0.63 (0.56 – 0.70) 0.49 (0.42 – 0.56)
C ( X→ Y ) cOR 2.22 (1.58 – 3.13) acOR 2.30 (1.62 – 3.26) 1.78 (1.29 – 2.46) 2.30 (1.62 – 3.26)
A-B ( X + M→ Y) cOR 2.03 (1.44 – 2.86) acOR 2.05 (1.44 – 2.91) 1.66 (1.20 – 2.30) 2.04 (1.43 – 2.90)
ß FIV
# OR 0.60 (0.53 – 0.67) OR 0.60 (0.52 – 0.67) 0.66 (0.58 – 0.74) 0.49 (0.43 – 0.56)
Explained proportion % 14 (0 – 34) 12 (0 – 43) 15 (0 - 38)
*Each pathway is shown in Fig. 1. X, independent variable (intervention- or control group). M, mediator variable (follow-up infarct volume), Y,
dependent variable (functional outcome)
# ß, coefficient of FIV (mediator) in pathwayA-Bmust be a significant predictor of the dependent variable, while controlling for the independent variable
cOR common odds ratio, acOR adjusted common odds ratio, 95% CI, 95% confidence interval





Reperfusion grades on DSA (%) and median follow-up infarct volumes
(ml) [IQR] #
0 18 (11) 107 [58-246] -
1 9 (5) 137 [62-222] -
2a 32 (19) 55 [30-118] -
2b 64 (39) 41 [21-93] -
3 43 (26) 56 [35-105] -
# Assessed by the modified Thrombolysis in Cerebral Infarction (mTICI):
0 – no reperfusion, 1 – antegrade flow past the initial occlusion, but
limited distal branch filling with little or slow distal reperfusion, 2a –
antegrade reperfusion of less than half of the previously ischaemic terri-
tory, 2b – antegrade reperfusion of more than half of the previously
ischaemic territory, 3 – complete antegrade reperfusion of the previously
ischaemic territory, with absence of visualised occlusion in all distal
branches. Scores were not available for 32 (19%) patients in the interven-
tion group
Eur Radiol
is automatically satisfied in our study due to randomisation of
treatment. Secondly, no unmeasured confounding between
mediator and outcome should be present. This is true for our
study as the observers were blinded with respect to clinical
information during imaging analysis [9]. Third, there should
be no unmeasured confounding between the treatment and
mediator. This requirement is also satisfied in our study due
to randomisation and the fact that FIV measurements were
assessed after baseline. This is also confirmed by the consis-
tency of the results of the adjusted and unadjusted analyses.
A limitation of our study is the exclusion of deceased pa-
tients in the first week after onset and therefore missing FIV
measurements at 5- to 7-day follow-up (n=60 (12%)). In our
sensitivity analysis, we tried to overcome this by imputing
FIVs in these deceased patients. Results of the sensitivity
analysis did not change the conclusions of our paper and effect
sizes are comparable. Although factors other than FIV possi-
bly play a role in early death, it is likely that the more severely
affected patients with potentially large FIV will be over-
represented among patients who died early [4, 6]. In our study,
no FIV measurements on NCCT in 99 patients could be
assessed at 5- to 7-day follow-up mostly because of logistic
reasons; this could result in a distortion of the results. We
therefore used imputation techniques to adjust for this poten-
tial bias [22, 23]. The estimates of the mediator (FIVmeasure-
ments) must be reliable and valid. Our automated, observer-
checked estimation method has been shown to be reliable
[17]. Overestimation of infarct size due to oedema may occur.
The randomised assessment of treatment effect will reduce
this bias. In a sensitivity analysis, we showed that use of 24-
h NCCT FIV for missing FIV did not increase the explained
proportion, probably because FIV measurement is less pre-
cise, and hypodense areas may yet increase in size.
Another limitation is our relatively small sample size. The
different pathways in our mediation model (EVT-FIV, FIV-
functional outcome and EVT- functional outcome) are all fre-
quently studied and confirmed in multiple datasets. However,
the proportion of the effect of EVTon functional outcome has
never been calculated before. Our relatively wide CI
expressed the uncertainty in this estimate. Therefore, our find-
ings need to be replicated in other randomised control trials
performed on EVT.
Our study made use of follow-up NCCT to assess FIV,
because this is the most widely available and used modality.
It would be of interest to also study effect mediation by FIV
measured with MRI. Care should be taken, however, that se-
lection bias in assessment does not distort the comparison
between MRI and CT.
A large proportion of the treatment effect on functional
outcome remains unexplained, suggesting FIV alone cannot
be used as an early proxy of functional outcome. Effects of
other pathways may play a role in determining functional
outcome such as infarct location. Previous studies have dem-
onstrated that certain brain regions are more sensitive than
others to hypoperfusion, which may interact with FIV regard-
ing functional outcome, given that the relevance for functional
outcome varies by regional eloquence [24–26]. In our study,
patients had an occlusion of the middle cerebral artery supply-
ing eloquent brain regions. Small lesions in eloquent regions
may have a larger destructive effect on functional outcome
than larger infarcts in non-eloquent regions.
Further studies should address the question whether com-
bining FIV with a measure of eloquence can increase the
predictive value for functional outcome [26, 27]. Taking elo-
quence into account might improve the proportion of ex-
plained mediated effect. The best method to combine elo-
quence, location and infarct volume is not yet known.
Infarcts do not only affect the cortical regions but also white
matter tracts. Small infarcts in eloquent cortical regions or
important white matter tracts might result in severe strokes.
This type of analysis, which takes into account the location of
infarct in mediation models, requires larger datasets. In our
study, wewere mainly interested in FIVas a surrogate imaging
biomarker as a first step, because it has been used in several
studies [28]. However, for further understanding of the path-
ophysiological mechanisms relating infarct volume to func-
tional outcome, taking location into account is the obvious
next step [26]. Another approach could be to combine the
FIV measurement with assessments of specific stroke symp-
toms and stroke severity. NIHSS is currently increasingly used
for assessment of initial stroke severity in clinical practice
[29–31], but it might also be an interesting intermediate out-
come measurement [16]. Also, in our primary analysis, we
assessed FIV at 5–7 days. FIV on NCCT in other time win-
dows might also be of interest as a surrogate marker [32].
Finally, the use of more advanced imaging modalities such





Recanalisation status on follow upCTA (%) andmedian follow-up infarct
volumes (mL) [IQR] #
0 16 (9%) 200 [65-324] 59 (31%) 93 [48-141]
1 4 (2%) 168 [104-231] 18 (9%) 103 [82-126]
2 15 (9%) 24 [12-61] 46 (24%) 82 [33-117]
3 138 (80%) 47 [23-86] 67 (35%) 51 [19-82]
# Assessed by the modified Arterial Occlusive Lesion (mAOL) score on
CTA at 24 h: 0 – no recanalisation of primary intracranial occlusion, 1 –
incomplete or partial recanalisation of the primary intracranial occlusion
without contrast passage, 2 – incomplete or partial recanalisation of the
primary intracranial occlusion with contrast passage, 3 – complete
recanalisation of the primary intracranial occlusion. Values were missing




as MRI to determine FIV would be interesting for future
studies.
In conclusion, we confirmed that intervention prevents pro-
gression of FIV on NCCT, but this only partly explains the
beneficial effect of intervention on functional outcome.
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